BMY - Bristol Myers wins FDA label expansion for CAR T therapy Abecma
2023-12-06 14:45:26 ET
More on Bristol-Myers
- Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better
- Bristol-Myers Squibb: The Patent Expiry Challenge
- Bristol Myers Squibb: A Bitter Pill But Still A Buy
- Bristol Myers gets priority review for urothelial cancer combination therapy
- Bristol Myers Squibb new CEO buys company shares
For further details see:
Bristol Myers wins FDA label expansion for CAR T therapy Abecma